Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
This comic conveys the absurdity of overreliance on symptom measures and excessive testing in contemporary clinical decision making and health care practice.
AMA J Ethics. 2020;22(9):E816-817. doi:
10.1001/amajethics.2020.816.
While useful in analyzing population trends in relative body weight, BMI possesses multiple shortcomings when used as an individualized health screening tool.
AMA J Ethics. 2023;25(7):E545-549. doi:
10.1001/amajethics.2023.545.
Lydia Smeltz, Susan M. Havercamp, PhD, and Lisa Meeks, PhD, MA
Lack of disability-competent health care contributes to inequitable health outcomes for persons with disabilities, the largest minoritized population in the world.
AMA J Ethics. 2024;26(1):E54-61. doi:
10.1001/amajethics.2024.54.
Lydia Smeltz joins Ethics Talk to discuss her article, coauthored with Drs Susan M. Havercamp and Lisa Meeks: “Aspiring to Disability Consciousness in Health Professions Training.”
Clinicians can support shared decision making by assessing patients’ knowledge, eligibility for screening, and preferences for engagement—active, collaborative, or passive—in the decision making process.
AMA J Ethics. 2015;17(7):601-607. doi:
10.1001/journalofethics.2015.17.7.ecas1-1507.